Sign in
4

Changes in Ownership

Roivant Sciences Ltd. Filed Acc 0001140361-25-037740

President & Immunovant CEO sold 665,159 shares at an average $16.21 ($10,781,813)

  • President & Immunovant CEO acquired 665,159 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Venker Eric President & Immunovant CEO 2025-10-06 Option exercise 10b5-1 +127,355 $15.85 $2,018,577 1,632,314 D
Venker Eric President & Immunovant CEO 2025-10-06 Option exercise 10b5-1 +24,900 $7.45 $185,505 1,657,214 D
Venker Eric President & Immunovant CEO 2025-10-06 Option exercise 10b5-1 +19,141 $3.85 $73,693 1,676,355 D
Venker Eric President & Immunovant CEO 2025-10-06 Sale 10b5-1 −171,396 $16.34 $2,800,611 1,504,959 D
Venker Eric President & Immunovant CEO 2025-10-07 Option exercise 10b5-1 +67,171 $15.85 $1,064,660 1,572,130 D
Venker Eric President & Immunovant CEO 2025-10-07 Option exercise 10b5-1 +107,131 $7.45 $798,126 1,679,261 D
Venker Eric President & Immunovant CEO 2025-10-07 Option exercise 10b5-1 +180,859 $3.85 $696,307 1,860,120 D
Venker Eric President & Immunovant CEO 2025-10-07 Sale 10b5-1 −355,161 $16.15 $5,735,850 1,504,959 D
Venker Eric President & Immunovant CEO 2025-10-08 Option exercise 10b5-1 +10,307 $15.85 $163,366 1,515,266 D
Venker Eric President & Immunovant CEO 2025-10-08 Option exercise 10b5-1 +128,295 $7.45 $955,798 1,643,561 D
Venker Eric President & Immunovant CEO 2025-10-08 Sale 10b5-1 −138,602 $16.20 $2,245,352 1,504,959 D
Derivatives
Venker Eric President & Immunovant CEO 2025-10-06 Option exercise · Stock Option (Right to Buy) 10b5-1 −127,355 1,054,528 D
Venker Eric President & Immunovant CEO 2025-10-06 Option exercise · Stock Option (Right to Buy) 10b5-1 −24,900 235,426 D
Venker Eric President & Immunovant CEO 2025-10-06 Option exercise · Stock Option (Right to Buy) 10b5-1 −19,141 6,457,382 D
Venker Eric President & Immunovant CEO 2025-10-07 Option exercise · Stock Option (Right to Buy) 10b5-1 −67,171 987,357 D
Venker Eric President & Immunovant CEO 2025-10-07 Option exercise · Stock Option (Right to Buy) 10b5-1 −107,131 128,295 D
Venker Eric President & Immunovant CEO 2025-10-07 Option exercise · Stock Option (Right to Buy) 10b5-1 −180,859 6,276,523 D
Venker Eric President & Immunovant CEO 2025-10-08 Option exercise · Stock Option (Right to Buy) 10b5-1 −10,307 977,050 D
Venker Eric President & Immunovant CEO 2025-10-08 Option exercise · Stock Option (Right to Buy) 10b5-1 −128,295 0 D
Open-market sales · 665,159 sh · avg $16.21 · $10,781,813
Loading xslF345X05/form4.xml…